EFFECT OF SODIUM HYDROSULFIDE ON COLLAGEN-INDUCED PLATELET AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC DISORDERS

Abstract

Objective: The purpose of the study was to study the influence of the sodium hydrosulfide (hydrogen sulfide's donor) on platelets’ aggregation in patients with arterial hypertension (AH) and metabolic disorders. Design and method: The study included 40 patients with AH and metabolic disorders 40–65 years old. Aggregation activity of platelets was studied by turbodimetric method on a two-channel laser analyzer. Functional activity of platelets was determined by the degree and the rate of collagen-induced aggregation of platelet-rich plasma, determined by the light transmittance curves and the average aggregate size. Sodium hydrosulfide was used in concentrations of 5 * 10–6 M and 5 * 10–7 M. Results: The present study revealed increase of the degree of platelet aggregation in patients with AH and impaired glucose tolerance compared to healthy donors. The addition of a hydrogen sulfide's donor caused further increase in the degree of aggregation, compared to aggregation without the addition of sodium hydrosulfide. In patients with AH and diabetes mellitus type 2 the degree of platelet aggregation was reduced compared to healthy donors. The addition of hydrogen sulfide's donor caused an increase in the degree of aggregation compared to the values of this parameter in the group of healthy volunteers. Conclusions: An increase in collagen-induced platelet aggregation under the influence of the hydrogen sulfide's donor was revealed in patients with arterial hypertension and metabolic disorders which may possibly be associated with an elevated adhesive and aggregation capacity of platelets. It also may indicate to the inadequacy of antiplatelet therapy, related to the prevention of cardiovascular diseases and their complications during AH. Therefore, the effect of hydrogen sulfide on platelet aggregation in patients with AH and metabolic disorders requires to be studied in more details.